ArticlePLoS pathogens2025
Valaciclovir therapy for secondary suppression of immune response to herpesviruses: An exploratory study.
Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Herpesviruses establish a state of persistent infection which is suppressed by sustained virus-specific immune control. The magnitude of this immune response can increase with age and lead to attrition of immune reserve against other pathogens. Approaches which suppress herpesvirus-specific immunity may therefore have the potential to improve general immune function. Anti-retroviral therapy for HIV leads to a reduction in HIV viral antigen and has been shown to mediate a secondary attenuation of the HIV-specific immune response. As such, we assessed if treatment with valaciclovir could suppress the immune response against cytomegalovirus and Epstein Barr Virus in donors aged >65 years. Medication was given at 3 different doses up to a maximum of 4gm/day for 6 months and humoral and cellular profiles were assessed over 12 months. Anti-viral therapy did not impact on the magnitude or phenotype of the humoral or cellular virus-specific immune response during the study period. Treatment also had no impact of physical or mental quality of life assessment. These data show that valaciclovir treatment, at this dose and treatment duration, does not attenuate the CMV or EBV-specific immune response in this age group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.